Lpath focuses on developing therapeutics that target bioactive lipids for treating a range of human diseases, including cancer and diseases that cause blindness. Its promising drugs have attracted attention -- and lots of money -- from Pfizer. More of both could be coming.
A New York City health code regulation set to go into effect on Jan. 1 would have added some disturbing images to the Big Apple's glittering background of advertising: Hideously accurate ads depicting the results of smoking. But a federal judge this week killed the city's anti-smoking campaign before it could begin.
The U.S. biotech is holding an analyst and investor meeting focused on the commercial potential of its multiple sclerosis drug Campath. The goal: to convince Paris-based Sanofi-Aventis to raise its hostile takeover offer in a battle that has now gone on for five months.
As pet cancer increases and pricier treatments become available, the cost of keeping a pet healthy is on the rise. DailyFinance writer Jonathan Berr shares the story of his family dog Ruby's bout with cancer. How much are you willing to spend on your best friend?
Wyeth Pharmecuticals on Wednesday lost its appeal of a decision that awarded $58 million in damages to three women who claimed the company's hormone-replacement drugs caused their breast cancer. The news could bode badly for the Pfizer-owned company, which has thousands of such cases pending.
Novartis will discontinue studies of an experimental lung-cancer cancer drug because of disappointing trial results.
Traditional chemotherapy for cancer patients is as dreaded as the disease itself. But Delcath's "Chemosaturation System," which is doing well so far in tests, promises to deliver treatments far more precisely, thus limiting side effects.
Dendreon's Provenge, which targets prostate cancer, catapulted that company's stock to record highs recently. Prima Biomed's CVac works similarly, but it has the potential to target multiple forms of cancer, giving the company an intriguing future.
A proposed Hodgkin's lymphoma treatment returned positive test results in a clinical trial, according to drugmaker Seattle Genetics Inc., which seeks to file the drug for approval with the U.S. Food and Drug Administration next year.
Shares of Celldex Therapeutics dove over 30% Friday after Pfizer abandoned its partnership with the small biotech to develop a brain cancer vaccine. Celldex says it will continue to develop the treatment alone.
Swiss pharmaceutical giant Roche has struck a deal with Aileron Therapeutics worth up to $1.1 billion to gain access to a new class of drugs called stapled peptide therapeutics. This could yield new ways to attack hard-to-reach disease targets.
It's been 15 years since The Kids in the Hall, the seminal sketch comedy show by the Canadian troupe of the same name, went off the air. Now they're finally back with a new show, Death Comes to Town.
